AEZS : Analysis & Opinions

  1. Aeterna Zentaris 3Q Loss $6M or 61c/Share (AEZS)

    November 9, 2016
    Aeterna Q3 EPS and revenue beat market expectations, and the outcome from two key drug studies may shape its future.
  2. Aeterna Signs Marketing Deal With STA (AEZS)

    October 13, 2016
    The commercialization of the cancer drug would be handled in Australia and New Zealand by Specialized Therapeutics Asia